【摘要】 目的 :研究NJ001识别抗原在人体内多种恶性肿瘤组织中的表达情况,并评估其与肿瘤分化的关系。方法 :采用免疫组化的方法对肺腺癌、肺鳞癌、胰腺癌、乳腺癌、食管癌、胃癌、肝癌和对应的良性病变组织中NJ001识别抗原的表达进行检测,同时与肿瘤分化程度进行比较,通过半定量的方法判定结果,使用χ~2检验或Fisher确切概率法进行相关性分析。结果:NJ001识别抗原在肺腺癌(88.0%)、肺鳞癌(82.2%)、胰腺癌(73.3%)和乳腺癌(57.8%)中均呈现出高表达,并且均与肿瘤分化程度显著相关(肺腺癌P<0.001,肺鳞癌P=0.002,胰腺癌P=0.002,乳腺癌P=0.024)。结论 :NJ001识别抗原有望为临床诊断肺腺癌、肺鳞癌、胰腺癌和乳腺癌及判断其分化程度提供一个新的肿瘤标志物。更多还原

【Abstract】 Objective:To examine NJ001 recognized antigen expression in surgically resected human malignant tumor tissues,and to evaluate the relationship between its expression and tumor differentiation. Methods:NJ001 recognized antigen expression was immunohistochemically studied in lung adenocarcinoma,lung squamous carcinoma,pancreatic cancer,breast cancer,esophageal cancer,gastric cancer,liver cancer and matched non-neoplastic tissues,and all positive cases were compared on tumor differentiation.The results were scored by semiquantitative analysis,and statistical analysis was evaluated by chi-square test or Fisher exact test.Results:Expression of NJ001 recognized antigen was significantly high in lung adenocarcinoma(88.0%),lung squamous carcinoma(82.2%),pancreatic cancer(73.3%)and breast cancer(57.8%),and was significantly correlated with lower differentiation degree in all these tumors(P < 0.001 in lung adenocarcinoma;P=0.002 in lung squamous carcinoma;P=0.002 in pancreatic cancer;and P=0.024 in breast cancer). Conclusion:NJ001 recognized antigen is expected to be a tumor marker in lung adenocarcinoma,lung squamous carcinoma,breast cancer and pancreatic cancer,as well as a remarkable biomarker for identification of differentiation degree in multiple neoplasms.更多还原